To explore the biological role of the PRG4/CD44 axis in further detail, we challenged HLE, HLF, and HLC19 HCC CD44-positive cells, and Hep3B and PLC/PRF/5 HCC CD44-negative cells with sorafenib and regorafenib in the presence/absence of rhPRG4 (Fig. 5). Here, PRG4 is linked to hepatocellular carcinoma.